1. Home
  2. EXP vs ERAS Comparison

EXP vs ERAS Comparison

Compare EXP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Materials Inc

EXP

Eagle Materials Inc

N/A

Current Price

$191.66

Market Cap

7.0B

Sector

Industrials

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$16.34

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXP
ERAS
Founded
1963
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.3B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
EXP
ERAS
Price
$191.66
$16.34
Analyst Decision
Hold
Strong Buy
Analyst Count
9
12
Target Price
$227.11
$14.25
AVG Volume (30 Days)
294.1K
3.3M
Earning Date
05-19-2026
05-08-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
36.23
EPS
3.29
N/A
Revenue
$495,023,000.00
N/A
Revenue This Year
$1.97
N/A
Revenue Next Year
$1.95
N/A
P/E Ratio
$59.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$171.99
$1.53
52 Week High
$245.53
$24.28

Technical Indicators

Market Signals
Indicator
EXP
ERAS
Relative Strength Index (RSI) 37.20 40.99
Support Level $188.79 $12.36
Resistance Level $226.04 $18.71
Average True Range (ATR) 5.14 1.20
MACD -0.72 -0.24
Stochastic Oscillator 10.69 15.04

Price Performance

Historical Comparison
EXP
ERAS

About EXP Eagle Materials Inc

Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: